Stockscreener 앱 받기
5.70
0.53%
0.03
시간 외 거래:
5.69
-0.010
-0.18%
Oric Pharmaceuticals Inc 주식(ORIC)의 최신 뉴스
ORIC Pharmaceuticals Inc Reports Q1 2025 Earnings: EPS Misses Estimate at -0.51, Revenue Remains at $0 Million - GuruFocus
Oric Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Oric Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates - GlobeNewswire
ORIC Pharma Secures Major J&J Partnership, Reports 5 Clinical Readouts Coming in Cancer Drug Pipeline - Stock Titan
Invesco Ltd. Grows Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals (ORIC) Rating Reiterated at HC Wainwright & Co. | ORIC Stock News - GuruFocus
Schonfeld Strategic Advisors LLC Buys New Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
Price T Rowe Associates Inc. MD Acquires 180,140 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
Boxer Capital Management LLC Purchases Shares of 1,732,571 ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by Adage Capital Partners GP L.L.C. - MarketBeat
ORIC Pharmaceuticals (ORIC) to Release Quarterly Earnings on Monday - Defense World
(ORIC) Long Term Investment Analysis - news.stocktradersdaily.com
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ORIC Stock News - GuruFocus
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Oncology Biotech ORIC Issues Major Equity Package: 32,400 Options Plus RSUs for New Talent - Stock Titan
An analyst sees good growth prospects for ORIC Pharmaceuticals Inc (ORIC) - Sete News
Market Watch: ORIC Pharmaceuticals Inc (ORIC)’s Noteworthy Drop, Closing at 5.57 - DWinneX
Is ORIC Pharmaceuticals Inc (ORIC) worth investing in despite its overvalued state? - uspostnews.com
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by Legal & General Group Plc - Defense World
ORIC Pharmaceuticals Inc’s Shares Reel: -51.58% Quarterly Revenue Decline Amid 401.98M Market Cap - investchronicle.com
ORIC Pharmaceuticals Inc (ORIC) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
79,900 Shares in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Acquired by Natixis - MarketBeat
ORIC-944 shows promise in prostate cancer treatment - Investing.com
ORIC Pharmaceuticals Highlights Promising Preclinical Data on OR - GuruFocus
ORIC® Pharmaceuticals Presents Preclinical Data to Support the P - GuruFocus
ORIC Pharmaceuticals Presents Preclinical Data To Support The Potential Of Oric-944 As A Best-In-Class PRC2 Inhibitor For The Treatment Of Prostate Cancer - marketscreener.com
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewswire
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Bought by Silverarc Capital Management LLC - MarketBeat
Diadema Partners LP Invests $1.73 Million in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $18.86 Average PT from Analysts - MarketBeat
A Look At The Behavior Of ORIC Pharmaceuticals Inc (ORIC) Stock - Stocksregister
Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Price Target at $18.86 - Defense World
ORIC Pharmaceuticals Inc (ORIC) produces promising results - uspostnews.com
Market Watch Highlights: ORIC Pharmaceuticals Inc (ORIC) Ends on an Downturn Note at 5.17 - DWinneX
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Position Increased by Geode Capital Management LLC - Defense World
ORIC Pharmaceuticals: Multiple Data Releases In 2025 Make It A Must-Watch Biotech - Seeking Alpha
ORIC Pharmaceuticals: Looking To The Horizon With Pivotal Study Plans (NASDAQ:ORIC) - Seeking Alpha
Alliancebernstein L.P. Trims Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
How the (ORIC) price action is used to our Advantage - news.stocktradersdaily.com
Is ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) the Best Biotech Penny Stock to Buy According to Hedge Funds? - MSN
13 Best Biotech Penny Stocks to Buy According to Hedge Funds - Insider Monkey
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Purchased by Vanguard Group Inc. - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Purchased by Wellington Management Group LLP - Defense World
Corebridge Financial Inc. Has $247,000 Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
KLP Kapitalforvaltning AS Makes New Investment in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Bought by American Century Companies Inc. - Defense World
ORIC Pharmaceuticals stock target holds at $21 by H.C. Wainwright - MSN
NEOS Investment Management LLC Buys New Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
ORIC Strengthens Team with Strategic Equity Grants to Key New Hires - Stock Titan
0.39%
3.66%
자본화:
|
볼륨(24시간):